|Bid||70.71 x 100|
|Ask||70.72 x 500|
|Day's Range||70.37 - 72.17|
|52 Week Range||63.76 - 88.85|
|PE Ratio (TTM)||7.44|
|Dividend & Yield||2.08 (2.94%)|
|1y Target Est||N/A|
Gilead Sciences, Inc. (NASDAQ:GILD) started climbing higher last week in anticipation of the announcement of the Senate Republicans’ health care bill, in which traders believed they would find good news for biopharmaceutical firms like GILD. This uptrend stalled briefly as a few Senate Republicans have balked at backing the bill, forcing a delay of a vote on the bill until after the July 4 recess, but we believe that consolidation is over.
Sameul Isaly, founder of one of the world’s most well-known healthcare funds, has made two key moves on Synergy Pharmaceuticals Inc (NASDAQ:SGYP) and Gilead Sciences Inc (NASDAQ:GILD). Isaly is the managing partner of OrbiMed, a global management firm that has assets under management of over $13 billion. Isaly is closely tracked by investors due to his exceptional track record: at the beginning of 2016, Barron’s said he was the only US mutual fund manager to beat the S&P 500 for an incredible 25 straight years.